Psoriatic Arthritis – Landscape & Forecast – Disease Landscape & Forecast (G7)

The psoriatic arthritis (PsA) treatment market is experiencing significant shifts with the introduction of newer targeted therapies, such as AbbVie’s Rinvoq and Skyrizi, and UCB’s bimekizumab. Additionally, the upcoming launch of new therapeutic agents is expected to influence market dynamics further, potentially challenging the longstanding dominance of TNF inhibitors. This shift is also driven by the growing adoption of biosimilars, which provide more cost-effective alternatives to high-priced branded treatments, along with the rise of novel therapies with unique mechanisms of action. Interleukin (IL)-17 and IL-23 inhibitors are positioned to garner substantial sales, potentially threatening the current market leaders, given the anticipated stability in diagnosis and drug-treatment rates. The impending entry of the first TYK2 inhibitor (BMS’s deucravacitinib), an IL-17 inhibitor (MoonLake Immunotherapeutics’ sonelokimab), and an IL-23 inhibitor (Sun Pharma’s tildrakizumab), among others, will also create interesting market dynamics.

Questions answered:

• What impact will current and emerging biosimilars have on the PsA therapy market in the coming years? How will physicians in the markets under study react to these less-expensive therapies?

• How will newer agents, especially those offering an alternative to the market-leading TNF inhibitors, change the PsA therapy market? What are physicians’ perceptions of these therapies?

• Which emerging therapies do dermatologists and rheumatologists consider the most promising for PsA? Which novel mechanisms of action are considered good clinical targets for this disease?

• What unmet needs remain in the treatment of PsA? Will emerging therapies fulfil these needs, and will they be competitive with biosimilars and entrenched branded therapies?

Content highlights:

Geography: United States, EU5, Japan.

Primary research: Country-specific interviews with thought-leading rheumatologists and dermatologists supported by survey data collected for this and other Clarivate research.

Epidemiology: Number of PsA patients by country, including diagnosed and drug-treated populations.

Forecast: 10-year, annualized, drug-level sales and patient share of key PsA therapies through 2034, segmented by brands / generics.

Product description

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
• Gauge the commercial outlook and impact of key market events,